title: Diminished HIV-specific CTL activity is associated with lower type 1 and enhanced type 2 responses to HIV-specific peptides during perinatal HIV infection.
abstract: The early development of symptoms and the rapid progression of disease in some vertically infected infants are thought to reflect in part the immaturity of their immune systems. We examined the relationship between HIV-specific CTL activity and the profile of cytokine production induced by mAb to CD3 and HIV envelope (env) peptides P18 and T1 in PBMC derived from 0.6- to 3.6-yr-old children with perinatal HIV infection. Cellular immunity against HIV was demonstrated only during early stages of disease, whereas the responses were either undetectable or at background levels in HIV-infected children with rapidly progressing disease and in uninfected children of HIV+ and HIV- mothers. Levels of IL-2 mRNA in anti-CD3 mAb- and env peptide-induced PBMC varied and were increased in the infected children with high frequencies of HIV-specific CTL precursors. Analysis of IFN-gamma and IL-4 production by CD4+ T cell clones obtained from cultures stimulated with anti-CD3 mAb or the env peptides showed an increased proportion of Th2 and Th0 clones in HIV-infected children with lower HIV-specific CTL activity, whereas children with high CTL activity had increased numbers of Th1 clones. The results of these studies suggest that decreases in CTL activity to the virus might be associated with the induction of a type 2 cytokine response. These findings underline the role of cytokines in the generation of HIV-specific CTL responses and may be important for the development of immunomodulatory and vaccine strategies to interrupt vertical transmission of HIV.
authors.affiliation: Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Wasik
authors.forename: P P
authors.initials: PP
authors.lastname: Jagodzinski
authors.forename: E M
authors.initials: EM
authors.lastname: Hyjek
authors.forename: J
authors.initials: J
authors.lastname: Wustner
authors.forename: G
authors.initials: G
authors.lastname: Trinchieri
authors.forename: H W
authors.initials: HW
authors.lastname: Lischner
authors.forename: D
authors.initials: D
authors.lastname: Kozbor
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D017252:CD3 Complex / Q000032:analysis / Q000276:immunology; D002478:Cells, Cultured; D002675:Child, Preschool; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical; D007371:Interferon-gamma / Q000096:biosynthesis; D007376:Interleukin-2 / Q000032:analysis; D015847:Interleukin-4 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D010455:Peptides / Q000276:immunology; D012333:RNA, Messenger / Q000032:analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007376:Interleukin-2; D010455:Peptides; D012333:RNA, Messenger; D014759:Viral Envelope Proteins; D015847:Interleukin-4; D007371:Interferon-gamma